EVOTAZ is a Oral Tablet in the Human Prescription Drug category. It is labeled and distributed by E.r. Squibb & Sons, L.l.c.. The primary component is Atazanavir Sulfate; Cobicistat.
Product ID | 0003-3641_0c387928-de94-40d6-b1d7-cfeed3801cbd |
NDC | 0003-3641 |
Product Type | Human Prescription Drug |
Proprietary Name | EVOTAZ |
Generic Name | Atazanavir And Cobicistat |
Dosage Form | Tablet |
Route of Administration | ORAL |
Marketing Start Date | 2015-01-29 |
Marketing Category | NDA / NDA |
Application Number | NDA206353 |
Labeler Name | E.R. Squibb & Sons, L.L.C. |
Substance Name | ATAZANAVIR SULFATE; COBICISTAT |
Active Ingredient Strength | 300 mg/1; mg/1 |
Pharm Classes | HIV Protease Inhibitors [MoA],Protease Inhibitor [EPC],UGT1A1 Inhibitors [MoA],UDP Glucuronosyltransferases Inhibitors [MoA],Cytochrome P450 3A4 Inhibitors [MoA],Cytochrome P450 3A Inhibitors [MoA],Cytochrome P450 2C8 Inhibitors [MoA],Cytochrome P450 3A Inhibitors [MoA],Cytochrome P450 3A Inhibitor [EPC],P-Glycoprotein Inhibitors [MoA],Cytochrome P450 2D6 Inhibitors [MoA],Organic Anion Transporting Polypeptide 1B1 Inhibitors [MoA],Organic Anion Transporting Polypeptide 1B3 Inhibitors [MoA],Breast Cancer Resistance Protein Inhibitors [MoA] |
NDC Exclude Flag | N |
Listing Certified Through | 2019-12-31 |
Marketing Start Date | 2015-01-29 |
NDC Exclude Flag | N |
Sample Package? | N |
Marketing Category | NDA |
Application Number | NDA206353 |
Product Type | HUMAN PRESCRIPTION DRUG |
Billing Unit | EA |
Marketing Start Date | 2015-01-29 |
Ingredient | Strength |
---|---|
ATAZANAVIR SULFATE | 300 mg/1 |
SPL SET ID: | 83db29d7-5d85-49d6-8cb6-740473365cf8 |
Manufacturer | |
UNII | |
RxNorm Concept Unique ID - RxCUI | |
UPC Code |
NDC | Brand Name | Generic Name |
---|---|---|
0003-3641 | EVOTAZ | atazanavir and cobicistat |
50090-1724 | EVOTAZ | atazanavir and cobicistat |
Mark Image Registration | Serial | Company Trademark Application Date |
---|---|
EVOTAZ 86092023 4765196 Live/Registered |
Bristol-Myers Squibb Company 2013-10-15 |